Oct 03, 2025 13:00
BCAB - BioAtla, Inc. Common Stock
Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
---|---|---|---|---|---|---|---|
0.8 0.05 (6.33%) | --- | --- | --- | 0.03 (3.16%) | 0.04 (4.67%) | 0.03 (3.05%) | 0.03 (3.05%) |
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -0.32
- Diluted EPS:
- -0.32
- Basic P/E:
- -2.6734
- Diluted P/E:
- -2.6734
- RSI(14) 1m:
- 100.0
- VWAP:
- 0.86
- RVol:
- 0.7754
Events
Period | Kind | Movement | Occurred At |
---|---|---|---|
1m | Price decrease 1m | 0.82 -0.01 (-1.17%) | Oct 15 15:57 |
1m | Price decrease 1m | 0.82 -0.01 (-1.06%) | Oct 15 15:53 |
1m | Price decrease 1m | 0.83 -0.01 (-1.15%) | Oct 15 15:34 |
1m | Price increase 1m | 0.85 +0.01 (+1.6%) | Oct 15 14:42 |
1m | Price decrease 1m | 0.83 -0.01 (-1.51%) | Oct 15 14:25 |
Related News
Aug 04, 2025 12:00
Jul 03, 2025 12:00
Apr 30, 2025 12:00
Dec 10, 2024 13:00
Oct 01, 2024 12:00
Jul 25, 2024 21:39
May 23, 2024 21:05
May 14, 2024 20:05
Apr 24, 2024 20:35